A pilot study of rimantadine for patients with chronic hepatitis C unresponsive to interferon therapy

OBJECTIVE:Therapeutic options are limited for chronic hepatitis C patients who have not responded to a course of interferon therapy. Recently, a 6-month course of amantadine was shown to result in a sustained virological response in chronic hepatitis C patients who were unresponsive to interferon therapy. The aim of this study was to evaluate the effect of rimantadine on chronic hepatitis C patients who had not responded to interferon therapy.METHODS:This was an open label trial involving 17 patients who were treated with rimantadine 100 mg b.i.d. for 6 months. Changes in serum aminotransferase activities and HCV-RNA levels were determined.RESULTS:Mean alanine aminotransferase activities and HCV RNA levels did not change significantly during therapy. HCV RNA remained detectable in all patients throughout therapy. Neurologic symptoms (headaches, nervousness, and dizziness) developed in 29% of patients. A total of 12% of patients required dose reduction after 12 wk of therapy because of dizziness.CONCLUSION:Rimantadine has no significant antiviral activity against HCV.

[1]  E. Keeffe,et al.  Re‐treatment of chronic hepatitis C with consensus interferon , 1998, Hepatology.

[2]  J. Lau,et al.  Virology of hepatitis C virus. , 1997, Clinics in liver disease.

[3]  G. Davis,et al.  Treatment of acute and chronic hepatitis C. , 1997, Clinics in liver disease.

[4]  A. Sanyal,et al.  Relationship between biochemical, virological, and histological response during interferon treatment of chronic hepatitis C , 1997, Hepatology.

[5]  C. Schroeder,et al.  Different modes of inhibition by adamantane amine derivatives and natural polyamines of the functionally reconstituted influenza virus M2 proton channel protein. , 1997, The Journal of general virology.

[6]  H. Thomas,et al.  Ribavirin treatment for patients with chronic hepatitis C: results of a placebo-controlled study. , 1996, Journal of hepatology.

[7]  T. Poynard,et al.  Meta‐analysis of interferon randomized trials in the treatment of viral hepatitis C: Effects of dose and duration , 1996, Hepatology.

[8]  S. Zeuzem,et al.  Comparison of two quantitative hepatitis C virus reverse transcriptase PCR assays , 1996, Journal of clinical microbiology.

[9]  O. Weiland,et al.  Combined treatment with interferon alpha‐2b and ribavirin for chronic hepatitis C in patients with a previous non‐response or non‐sustained response to interferon alone , 1995, Journal of medical virology.

[10]  M. Nahata,et al.  Rimantadine: A Clinical Perspective , 1995, The Annals of pharmacotherapy.

[11]  L. Stuyver,et al.  Typing of hepatitis C virus isolates and characterization of new subtypes using a line probe assay. , 1993, The Journal of general virology.

[12]  K. Martin,et al.  Nuclear transport of influenza virus ribonucleoproteins: The viral matrix protein (M1) promotes export and inhibits import , 1991, Cell.

[13]  R. Belshe,et al.  Pharmacokinetics of rimantadine hydrochloride in patients with chronic liver disease , 1987, Clinical pharmacology and therapeutics.

[14]  Y. Ghendon,et al.  Influence of membrane (M) protein on influenza A virus virion transcriptase activity in vitro and its susceptibility to rimantadine , 1980, Journal of virology.

[15]  O. Weiland,et al.  Randomised, double-blind, placebo-controlled trial of interferon alpha-2b with and without ribavirin for chronic hepatitis C. The Swedish Study Group. , 1998, Lancet.